Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 9.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,855 shares of the medical equipment provider's stock after acquiring an additional 1,440 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in ResMed were worth $4,349,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ballentine Partners LLC grew its stake in shares of ResMed by 6.3% during the 1st quarter. Ballentine Partners LLC now owns 1,782 shares of the medical equipment provider's stock worth $399,000 after purchasing an additional 105 shares during the period. Inspire Investing LLC grew its position in ResMed by 29.3% during the first quarter. Inspire Investing LLC now owns 28,578 shares of the medical equipment provider's stock worth $6,397,000 after buying an additional 6,472 shares during the period. Intech Investment Management LLC grew its position in ResMed by 63.2% during the first quarter. Intech Investment Management LLC now owns 15,325 shares of the medical equipment provider's stock worth $3,430,000 after buying an additional 5,934 shares during the period. Goldman Sachs Group Inc. increased its holdings in ResMed by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 739,007 shares of the medical equipment provider's stock valued at $165,427,000 after buying an additional 58,155 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of ResMed by 2.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 977,401 shares of the medical equipment provider's stock valued at $218,791,000 after acquiring an additional 22,789 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.
Insider Activity
In other ResMed news, General Counsel Michael J. Rider sold 100 shares of ResMed stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $274.36, for a total value of $27,436.00. Following the completion of the sale, the general counsel owned 11,327 shares in the company, valued at $3,107,675.72. The trade was a 0.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John Hernandez sold 2,575 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $287.10, for a total transaction of $739,282.50. Following the transaction, the director owned 4,045 shares in the company, valued at approximately $1,161,319.50. The trade was a 38.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,734 shares of company stock valued at $3,019,169 over the last quarter. Company insiders own 0.71% of the company's stock.
ResMed Stock Performance
Shares of NYSE RMD opened at $281.76 on Tuesday. The company has a 50-day simple moving average of $278.33 and a 200-day simple moving average of $254.34. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.44 and a quick ratio of 2.53. The company has a market cap of $41.12 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 1.87 and a beta of 0.83. ResMed Inc. has a 12 month low of $199.92 and a 12 month high of $293.81.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical equipment provider reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.08. ResMed had a net margin of 27.22% and a return on equity of 25.62%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the firm posted $2.08 earnings per share. The company's quarterly revenue was up 10.2% compared to the same quarter last year. On average, equities analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.
ResMed Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 18th. Stockholders of record on Thursday, August 14th were given a $0.60 dividend. This is an increase from ResMed's previous quarterly dividend of $0.53. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 14th. ResMed's dividend payout ratio (DPR) is presently 25.24%.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on RMD. Wall Street Zen cut ResMed from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Royal Bank Of Canada raised their price target on ResMed from $294.00 to $300.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. CLSA raised ResMed from a "hold" rating to an "outperform" rating in a research note on Tuesday, September 2nd. Citigroup started coverage on shares of ResMed in a research note on Thursday, September 18th. They issued a "buy" rating and a $330.00 price objective on the stock. Finally, KeyCorp lifted their target price on shares of ResMed from $274.00 to $298.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $294.20.
View Our Latest Research Report on RMD
ResMed Company Profile
(
Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report